Skip to content
Therapy But Better – Lifestyle
Author:
EIT Pharma
EIT Pharma to Sponsor and Present at the 2026 Delta Cure International Meeting
October 13, 2026
EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners
August 31, 2026
EIT Pharma Announces FDA Acceptance of New Drug Application for Lonafarnib for Treatment of Chronic Hepatitis D
August 11, 2026
EIT Pharma Highlights New Lonafarnib Analyses at EASL Congress 2026
June 1, 2026